MNKD
MannKind CorporationNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
131.37
PEG
—
P/B
-14.98
P/S
2.21
EV/EBITDA
22.48
DCF Value
$-50.54
FCF Yield
1.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
76.4%
Operating Margin
11.1%
Net Margin
1.7%
ROE
-11.2%
ROA
0.8%
ROIC
5.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $112.0M | $-15.9M | $-0.05 |
| FY 2025 | $349.0M | $5.9M | $0.02 |
| Q3 2025 | $82.1M | $8.0M | $0.03 |
| Q2 2025 | $76.5M | $668.0K | $0.00 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.04
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.